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Misuse of and dependence on codeine-containing products is 
on the increase globally.[1] The problem does not only lie with 
over-the-counter (OTC) products where they are available, but 
also with inappropriate prescribing of codeine-containing medi-
cations. [1,2] Misuse refers to ‘the use of a medicine, with or without 
a doctor’s prescription, clearly outside of accepted medical practice 
or guidelines, for recreational purposes or in the framework of 
self-medication, in greater dosages or for longer periods than 
were indicated, in which the risks and problems associated with 
use outweigh the benefits’.[3] Dependence refers to a diagnosable 
psychiatric condition.
Less than 45% of prescribing professionals (mainly general 
practitioners (GPs)) working in the UK indicated that codeine 
dependence could be effectively managed in general practice 
settings. [4] The corresponding percentages for Ireland and South 
Africa (SA) were 43% and 35%, respectively.[5] As a result, individuals 
who are misusing or dependent on codeine are increasingly being 
seen in specialist substance abuse treatment centres.[6] Research in SA 
has indicated that there were 435 admissions to specialist substance 
abuse treatment centres for codeine misuse or dependence in 2014, 
translating to ~2.5% of individuals seen in such settings.[7] This is 
fairly similar to figures from the UK (2.2%) and Ireland (1.9%).[6] 
However, these figures do not include individuals treated at public 
or private psychiatric treatment facilities.
Objectives
The focus of this study was to complement previous epidemiological 
research[1] and research on pharmacists[8] and GPs[5] conducted in 
SA by investigating the perspectives of addiction treatment providers 
regarding treatment for codeine misuse or dependence. Specific 
objectives included documenting: (i) the kinds of professionals 
providing treatment; (ii) the settings in which treatment is provided; 
(iii) the kinds of interventions delivered; (iv) the reasons patients come 
to treatment for codeine-related problems; (v) the barriers to their 
accessing treatment; (vi) the training needs for addiction treatment 
providers in terms of addressing codeine misuse and dependence; 
(vii)  the best means for receiving additional training, should it be 
required; and (viii) ways to improve treatment or initiate innovations 
in this area. Similar research conducted in the UK and Ireland will 
be reported in detail elsewhere. This study was conducted as part of 
the SA arm of the comprehensive, multicountry Codeine Use, Misuse 
and Dependence (CODEMISUSED) study funded by the European 
Commission to inform the design of pharmacy screening and brief 
interventions, risk management, monitoring and surveillance, 
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continuing professional development training, and the development of 
specific clinical/community pharmacy treatment protocols.
Methods
Design
The study was cross-sectional.
Sampling
Participants comprised 15 addiction treatment providers from cen-
tres participating in the South African Community Epidemiology 
Net work on Drug Use (SACENDU) and five members of the South 
Afri can Addiction Medicine Society (SAAMS). SACENDU (http://
www.mrc.ac.za/adarg/sacendu.htm) comprises 78 treatment centres 
across SA’s nine provinces. The 15 participants were selected from 
11 treatment centres with the highest number of patients in treat ment 
for codeine-related problems in 2014. The five members of SAAMS 
(http://www.saams.co.za/) comprised members of the execu tive com-
mittee of that society. To qualify for inclusion in the study, participants 
had to have treated someone who had either mis used codeine or was 
dependent on codeine in the past 12 months. This number was settled 
on based on expectations of the number of participants that we would 
need to reach before we would get satu ration based on SACENDU 
data on the number of centres where codeine patients had received 
treatment in 2014, typical practice in other qualitative studies,[9] and 
the human resources and funding available.
Procedures
The focus of the interview was on the providers’ experience of patients/
clients as a collective, and it lasted between 20 and 30 minutes. 
Following invitation via the treatment listing, and receipt of informed 
consent, interviews were conducted telephonically by the principal 
investigator (CDHP) or a senior scientist (ER) who has training in 
research psychology, with support from seconded research staff who 
were given training on how to take notes during the interviews. Ethical 
approval for the study was required, and was granted by the South 
African Medical Research Council (ref. no. EC022-11/2013).
Instrument
A semi-structured interview comprising 20 questions (8 qualitative 
and 12 quantitative) was conducted with the addiction treatment 
providers. The interview drew on questions asked in the 
CODEMISUSED surveys of GPs and pharmacists as well as on a 
report on OTC and prescription-only medicines produced by the 
National Treatment Agency for Substance Misuse in the UK.[10] 
It included sections covering demographics of respondents and 
treatment setting characteristics, experience with treating codeine 
patients, and general questions about treatment for individuals with 
codeine dependence, including new approaches or innovations.
Data analysis
The quantitative data were analysed using descriptive statistics 
(e.g. frequencies and cross-tabulations). The qualitative data that 
emerged from the open-ended questions in the survey were coded 
and analysed using thematic analysis. As the number of participants 
was low and the data emerging from the qualitative questions were 
straightforward, the themes were coded by hand.
Results
Profile of participants and their treatment settings
Three-quarters of respondents were female, with the highest propor-
tion being in the 30 - 49-year age bracket (Table 1). The respondents 
held a variety of posts and worked in a number of specialties, 45% 
being social workers. Half of the respondents had ≤10 years of ser-
vice. The proportion who had received specialist training was low, 
with only two of 20 participants (both addiction medicine special-
ists) indicating that they had received specific training on codeine 
management, one in Australia and one via a conference. However, 
many had received training in the management of individuals with 
opioid dependence, including pharmacotherapy (methadone and 
buprenorphine-naloxone).
With regard to the types of treatment setting in which the res-
pondents worked, roughly two-thirds worked in partially state-
Table 1. Demographic profile of respondents (N=20)
n (%)
Gender
Male 5 (25.0)
Female 15 (75.0)
Age (years)
20 - 29 2 (10.0)
30 - 49 14 (70.0)
50 - 69 4 (20.0)
Duration of practice in substance abuse 
(years)
1 - 10 10 (50.0) 
11 - 20 8 (40.0)
≥21 2 (10.0)
Profession
Psychiatrist 4 (20.0)
Psychologist 1 (5.0)
Social worker 9 (45.0)
Addiction counsellor 1 (5.0)
Nurse 2 (10.0)
Specialist methadone-prescribing doctor 0 (0)
BPsych or other training in psychology 3 (15.0)
Received any specialist training in codeine 
misuse/dependence 
Yes 2 (10.0)
No 18 (90.0)
Table 2. Type of setting in which practitioners work and 
nature of treatment (N=20)
n (%)
Setting
Fully state-funded treatment centre 2 (10.0)
Partially state-funded treatment centre 13 (65.0)
Private practice (for profit) 1 (5.0)
Registered charity 0 (0)
Private practice with other partners 2 (10.0)
Sole private practice 0 (0)
Other – community mental health service 0 (0)
Other 2 (10.0)
Client location
Urban 14 (70.0)
Rural 2 (10.0)
Mixed 4 (20.0)
Type of treatment
Inpatient 8 (40.0)
Outpatient 4 (20.0)
Mixed 8 (40.0)
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funded treatment centres (Table 2). Few of the settings catered to 
predominantly rural clients, with most being located in urban settings. 
Only four of the participants indicated that they worked in settings 
catering for outpatients alone. Most of the treatment carried out in SA 
extended over a period of ≤10 weeks, and included pharmacotherapy, 
psychosocial therapy, cognitive behavioural therapy, motivational 
interviewing, psychodynamic therapy and support groups.
Type of treatment provision for codeine misuse  
and dependence
The number of codeine patients seen per treatment provider per 
year varied substantially, ranging between 1 and 250 (mean 41.4) 
The largest numbers of patients with codeine misuse or dependence 
were treated by addiction medicine specialists (on average 107.4 
per year), but the data were very skewed, and the median number 
of codeine patients seen per year for all 20 providers interviewed 
was only 6 and the mode was 1. Over half of the settings in which 
the practitioners worked provided detoxification, pharmacotherapy 
(e.g. buprenorphine-naloxone, buprenorphine or methadone) 
and psychosocial therapy (cognitive behavioural therapy (CBT), 
motivational interviewing (MI) and psychodynamic therapy), with 
CBT being the most common, followed by MI and aftercare (Table  3). 
Seven of the practitioners indicated that the settings in which they 
worked provided other treatment modalities such as support groups 
(including Narcotics Anonymous and Alcoholics Anonymous), 
family intervention therapy, lectures and alternative therapies such 
as reflexology, relaxation therapy, acupuncture, aromatherapy, drama 
therapy and occupational therapy.
Six out of 10 treatment programmes were described as fixed and 
not specifically tailored to patients’ individual needs. Psychosocial 
interventions were most common, followed by detoxification and 
pharmacotherapy (e.g. buprenorphine). Roughly three-quarters of all 
treatment for codeine misuse was ≤10 weeks in duration, spread fairly 
evenly between the ≤4 weeks, 5 - 6 weeks and 7 - 10 weeks categories.
Characteristics of codeine patients
Therapeutic misuse and dependence for pain/opiate withdrawals, 
and intentional misuse for intoxication, were reported as main rea-
sons for seeking treatment (Table 4). Participants reported a variety 
of specific barriers to treatment for individuals experiencing codeine 
misuse and dependence. Most common was the report that patients 
were in denial of a problem, not ready for change, and/or had mental 
health problems. Barriers related to affordability (60%), not knowing 
where to go for treatment, and stigma associated with going to a drug 
treatment centre (85%) also rated very high.
In the event of treatment of a patient with coexisting pain and 
addiction to codeine medicines, participants observed difficulties 
in the treatment of physical pain (sometimes also emotional pain) 
and opiate dependence at the same time, requiring integrated pain 
and addiction specialist services as well as primary care involvement 
and specific care pathways. Participants referred to the need to 
provide alternative non-opioid pain relief in such patients (n=12); 
the need to refer to outside services, and particularly for pain 
specialists/clinics, psychologists, psychiatrists or GPs; and the need 
for physiotherapy, biokinetics, acupuncture, relaxation therapy and 
even antidepressants.
Education and training of addiction treatment providers
All the participants felt that they would benefit from further training 
in the area of codeine misuse and dependence (Table 5), and that 
this training would be most useful in the form of a face-to-face 
multidisciplinary workshop. When questioned around availability 
of best-practice guidelines for the treatment of codeine misuse 
and dependence, participants reported that specific protocols on 
the treatment and detoxification of patients who are dependent 
on codeine, and how best to address less severe codeine-related 
problems, would be very helpful. Four of the five members of SAAMS 
referred to their SAAMS guidelines for managing opiate dependence. 
Three participants from other treatment centres also referred to 
general opiate guidelines, which are not specific to codeine and often 
Table 3. Nature of treatment for codeine misuse and 
dependence
n (%)
Type of intervention*
Detoxification 11 (55.0)
Pharmacotherapy 11 (55.0)
Psychosocial treatment 13 (65.0)
Aftercare 13 (65.0)
Other 7 (35.0)
Nature of treatment
Flexible 8 (40.0)
Fixed 12 (60.0)
Both 0 (0)
Average length of treatment (weeks) (N=18)
≥25 1 (5.6)
21 - 24 1 (5.6)
11 - 20 2 (11.1)
7 - 10 5 (27.8)
5 - 6 4 (22.2)
≤4 5 (27.8)
*Not mutually exclusive.
Table 4. Reasons why codeine-dependent patients came for 
treatment, and barriers to treatment (N=20)
n (%)
Reasons for treatment*
 Therapeutic misuse and dependence for pain and 
opiate withdrawals (iatrogenic dependence)
9 (45.0)
 Intentional misuse for intoxication and dependence 
in response to excessive/long-term use
13 (65.0)
Intentional misuse to manage anxiety 0 (0)
Barriers to treatment*
Denial of problem 16 (80.0)
Not ready for change 10 (50.0)
Fear of treatment 7 (35.0)
 Other mental health problems  
(e.g. depression, anxiety) 
11 (55.0)
Lack of awareness of where to go for treatment 7 (35.0)
 Stigma associated with going to drug treatment centre 17 (85.0)
Language barriers 2 (10.0)
Child-care issues 6 (30.0)
Geographical location of treatment centres 2 (10.0)
Belief that treatment is not effective/does not work 5 (25.0)
Affordability of services 12 (60.0)
Transport costs and barriers 0 (0)
Unaware they are addicted 8 (40.0)
Others† 6 (30.0)
*Not mutually exclusive.
†These were fear of going through withdrawal (n=2), and n=1 each for problems 
associated with taking time off work, not wanting to have inpatient treatment, religious 
beliefs, and ‘psychosocial considerations’.
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have a focus on heroin, and three treatment providers stated that 
they used internally developed guidelines. Ten participants indicated 
that they were not sure or were unaware of any such guidelines for 
codeine-specific cases, or stated categorically that there were no such 
guidelines. One participant stated that their rule of thumb was to use 
buprenorphine-naloxone and to stay away from benzodiazepines.
Awareness of new approaches, best practices and 
innovations in the treatment of codeine misuse and 
dependence
Twelve treatment providers were unaware of new approaches to the 
management of codeine misuse. Seven of the participants, however, 
mentioned the Codeine Care Initiative (http://selfcare247.co.za/247-
codeine-care-initiative/). There seems to be some doubt as to how well 
the Codeine Care Initiative is working. Additional comments centred 
on the need for patient education (n=4) and the need for better 
training of health professionals, including psychiatrists, pharmacists, 
and in particular GPs (n=9). Increased pharmacovigilance was also 
stressed by several participants, together with increasing aftercare 
services following treatment of individuals misusing or dependent on 
codeine, better sharing of information within and across sectors, and 
increasing community-based addiction services in general.
Discussion
The majority of addiction treatment providers who participated were 
female, were aged 30 - 49 years, and had 1 - 10 years’ experience in 
substance abuse treatment provision. The most common profession 
was social work, followed by psychiatry. Only two of the 20 partici-
pants confirmed that they had received specialist training in codeine 
misuse and dependence. Over half of the settings in which the 
practitioners worked provided detoxification, pharmacotherapy and 
psychosocial therapy. In common with other studies, denial of having 
a problem was listed as the biggest barrier preventing individuals 
misusing or dependent on codeine from coming to treatment, 
followed by not being ready for change and lack of awareness of where 
to go for treatment.[11-13] Research has shown that codeine users can 
feel ashamed when they realise they are dependent. Many perceive 
themselves as respectable, professional and highly functioning, and 
struggle to view themselves as an ‘addict’. Desperately trying to keep 
their problem a secret from family members and colleagues prevents 
many from seeking treatment.[13]
Qualitative research recently conducted in SA and Ireland 
furthermore underscores the lack of awareness of risk around habit-
forming use of medicines containing codeine and pathways towards 
dependence in patients who attended treatment.[14,15] Stigma was 
listed as less of a problem in SA compared with data obtained from 
the UK and Ireland as part of the CODEMISUSED project,[16] but in 
SA and Ireland child-care issues were raised more frequently than in 
the UK. Six out of 10 addiction treatment providers surveyed in SA 
indicated that affordability of services would be a barrier to codeine 
patients accessing treatment, compared with only 22% in Ireland and 
none in the UK, where there is a National Health Insurance system.[16] 
In SA, public sector drug treatment facilities are only available in the 
Western Cape, Gauteng, Mpumalanga, KwaZulu-Natal and Limpopo 
provinces.[17] Codeine misusers in rural areas in particular face many 
problems in accessing treatment, as many are unemployed, they 
generally do not have a support system for child care, and transport 
costs are high. In a study conducted in Cape Town, financial and 
geographical factors were found to be barriers to poorer people 
accessing substance abuse treatment in general.[18] Most people were 
reluctant to spend time travelling on costly public transport, and 
people were also reluctant to pay for treatment, as they were often 
aware that there were government-funded centres available – albeit 
with a lengthy waiting list.[14] Surprisingly, only 10% of our SA 
participants indicated that the geographical location of treatment 
settings would be a problem, compared with 22% for Ireland, and 
none mentioned transport-related costs as being a barrier for codeine 
patients in SA, compared with 30% for Ireland.[16]
Practitioners were optimistic about preventing relapse by the use of 
alternative non-opioid pain relief in patients with coexisting pain and 
addiction to codeine medicines. In such instances they also reported 
referring to other professionals such as pain specialists/clinics, 
psychologists and psychiatrists, and recommending alternative treat-
ments such as acupuncture or relaxation therapy. In contrast, 
treatment providers in both the UK and Ireland were pessimistic 
about positive outcomes when dealing with patients with coexisting 
pain and codeine dependence, with Irish practitioners reporting that 
poorer outcomes were likely.[16]
Almost half of the participants highlighted the need for better 
training of health professionals in managing codeine-related prob-
lems. Previous research has indicated that such training is needed 
for a broad range of health professionals, including psychiatrists, 
pharmacists, and in particular GPs.[4] Best-practice guidelines for 
the management of opioid use disorders have been developed by 
SAAMS,[19] but few of the non-medical treatment providers surveyed 
were aware of them. Furthermore, these guidelines and those from 
countries such as Australia and New Zealand are not specific to 
individuals dependent on codeine and tend to focus on stronger 
opioids such as heroin.[20,21] According to Nielsen et al.,[22] there are 
many differences between individuals seeking treatment who are 
dependent on codeine as opposed to strong prescription opioids. The 
most common reason for use of prescription opioid analgesics in both 
groups was to resolve pain, although only the codeine-dependent 
group reported initiation due to acute pain such as toothache or 
headaches. This could imply that the latter group have less contact 
with health professionals and are more likely to self-medicate. They 
were also less likely to report heroin use and had a higher proportion 
of female users. However, the main difference between the two groups 
Table 5. Training needs in the area of codeine misuse and 
dependence and best means of receiving training (N=20)
n (%)
Training needs*
How to manage withdrawal/detoxification 5 (25.0)
 Psychological treatment including motivational 
interviewing
4 (20.0)
Management of chronic pain in codeine users 0 (0)
Pharmacotherapy 0 (0)
New modalities and innovations in treatment 3 (15.0)
Early identification of codeine misuse 0 (0)
Depression and codeine misuse/dependence 0 (0)
Types of codeine use and effects 1 (5.0)
Relapse prevention 3 (15.0)
Where to make referrals 1 (5.0)
All aspects of codeine use and treatment 1 (5.0)
Best form of further training*
Internet-based training 5 (25.0)
Face-to-face lecture 6 (30.0)
Face-to-face workshop 16 (80.0)
One-week course 4 (20.0)
Other (audit and practice record keeping) 3 (15.0)
*Not mutually exclusive.
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was that the codeine group was less likely to enter maintenance 
treatment, which may indicate that health professionals wrongly 
assume that a shorter duration of treatment is needed, as they believe 
such patients have a milder opioid dependence.[22] Similar to their 
counterparts in the UK and Ireland,[16] our study participants believed 
that this training should take place in a workshop or lecture format, 
i.e. face to face rather than online. In addition to training in the 
management/treatment of codeine misuse and managing withdrawal 
and detoxification, SA participants (in contrast to colleagues in the 
UK and Ireland[16]) also wanted training in relapse prevention.
Several participants stressed that increased pharmacovigilance 
was also needed, together with increased aftercare services following 
treatment of individuals misusing or dependent on codeine, 
better sharing of information within and across sectors, and more 
community-based addiction services in general.[23] Many of these 
interventions were also identified as being important in interviews 
conducted with key national stakeholders from a variety of sectors 
beyond addiction practice in the UK, Ireland and SA in another 
component of the CODEMISUSED project.[24]
Study limitations
This study is subject to several limitations. First, the number of 
participants was small and participants were identified by purposeful 
sampling, which could limit the generalisability of the findings more 
broadly. However, in terms of participants recruited from centres 
participating in SACENDU, they do represent treatment providers 
working in centres seeing substantial numbers of patients who are 
treated for codeine-related problems. The participants recruited via 
SAAMS (n=5) may also have been biased towards those who are 
more senior and experienced, given that they were exco members of 
this society. Nevertheless, given their experience, their insights are 
likely to be of value. The profiles of the participants varied widely, 
especially with regard to professions, skills, experience and training 
in the field of addiction, which is likely to have had an effect on the 
results. More nuanced research is needed in future, to go into more 
depth on interventions likely to be provided by addiction treatment 
providers with different professional backgrounds.
Recommendations
While we do not have good outcomes data on the effectiveness of the 
treatment of individuals misusing or dependent on codeine in SA, we 
do know that over a third (37%) of codeine patients treated in centres 
participating in SACENDU had previously received treatment for the 
same condition, and that many of the addiction treatment providers 
participating in the research highlighted the need for better training 
of health professionals in managing codeine-related problems. In 
view of this, specific best-practice guidelines for managing codeine 
misuse and dependence should be developed and/or updated to 
incorporate innovations to ensure that individuals misusing or 
dependent on codeine receive a uniform and proven treatment 
option.[14,15,25] Availability of opioid agonists should probably be 
expanded to low-threshold services in the treatment of codeine 
dependence.[26] The training needs of treatment providers should be 
addressed as a matter of urgency to cover best practices for managing 
codeine misuse and dependence, including detoxification modalities, 
pharmacotherapy maintenance treatment, psychosocial support and 
ensuring proper aftercare.[24]
Given the relatively low numbers of individuals in treatment 
for codeine-related problems[5] and the possible barriers that may 
make it harder for them to access treatment, active steps are needed, 
in particular to address denial of the problem and fear of being 
stigmatised. This first needs to be verified by research conducted 
among codeine-dependent patients themselves. Among other things, 
appropriate responses might include increasing media coverage of 
the problem of codeine misuse and dependence, and public health 
campaigns highlighting that anyone can become addicted to codeine 
products when used in the long term or excessively.[13,24] Awareness 
campaigns should also educate the public on where they can go to 
seek help.
Conclusions
There appears to be a broad spread of individuals providing treatment 
for persons misusing or dependent on codeine. They have general 
training in the provision and management of opioid agonist treatment, 
but few have specifically been trained in the management of codeine-
related misuse/dependence. Further training may need to centre on 
how to manage withdrawal and detoxification, titration of the correct 
dosage of agonist therapies, psychological interventions and relapse 
prevention. The main barriers to patients entering treatment were 
seen as denial of having a problem, not being ready for change, mental 
health problems, stigma associated with going to a drug treatment 
centre, not knowing where to access treatment, and affordability. 
While further investigation is still needed, including research among 
codeine patients in treatment, consideration should be given to 
campaigns that highlight that anyone can become dependent on 
codeine products used in the long term or excessively, addressing 
concerns associated with the stigma of going to a drug treatment 
centre as a person misusing or dependent on codeine, and addressing 
the affordability of drug treatment in general and where to go for help.
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